Ponvory is a drug owned by Vanda Pharmaceuticals Inc. It is protected by 6 US drug patents filed from 2021 to 2024. Out of these, 5 drug patents are active and 1 has expired. Ponvory's patents have been open to challenges since 18 March, 2025. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 10, 2042. Details of Ponvory's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9062014 | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(6 years from now) | Active |
| USRE43728 | Thiazolidin-4-one derivatives |
Nov, 2029
(4 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11951097 | Methods of treating multiple sclerosis |
Oct, 2042
(17 years from now) | Active |
| US10220023 | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(10 years from now) | Active |
| US8273779 | Thiazolidin 4-one derivatives |
Dec, 2025
(7 months from now) | Active |
| US9000018 | Thiazolidin-4-one-derivatives |
Nov, 2024
(5 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ponvory's patents.
Latest Legal Activities on Ponvory's Patents
Given below is the list of recent legal activities going on the following patents of Ponvory.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 20 Jun, 2024 | US8273779 |
| Change in Power of Attorney (May Include Associate POA) Critical | 20 Jun, 2024 | US9000018 |
| Change in Power of Attorney (May Include Associate POA) Critical | 20 Jun, 2024 | US9062014 |
| Email Notification Critical | 20 Jun, 2024 | US9000018 |
| Email Notification Critical | 20 Jun, 2024 | US9062014 |
| Change in Power of Attorney (May Include Associate POA) Critical | 20 Jun, 2024 | US8273779 |
| Email Notification Critical | 18 Jun, 2024 | US11951097 |
| Change in Power of Attorney (May Include Associate POA) Critical | 18 Jun, 2024 | US11951097 |
| Maintenance Fee Reminder Mailed Critical | 13 May, 2024 | US8273779 |
| Post Issue Communication - Certificate of Correction | 08 May, 2024 | US11951097 |
FDA has granted several exclusivities to Ponvory. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Ponvory, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Ponvory.
Exclusivity Information
Ponvory holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Ponvory's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Several oppositions have been filed on Ponvory's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Ponvory's generic, the next section provides detailed information on ongoing and past EP oppositions related to Ponvory patents.
Ponvory's Oppositions Filed in EPO
Ponvory has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 21, 2022, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP15807916A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15807916A | Oct, 2022 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP15807916A | Oct, 2022 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
US patents provide insights into the exclusivity only within the United States, but Ponvory is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ponvory's family patents as well as insights into ongoing legal events on those patents.
Ponvory's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ponvory's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 10, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ponvory Generics:
There are no approved generic versions for Ponvory as of now.
Alternative Brands for Ponvory
Ponvory which is used for reducing circulating lymphocytes in treating relapsing forms of multiple sclerosis in adults., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Bristol |
| |||
About Ponvory
Ponvory is a drug owned by Vanda Pharmaceuticals Inc. It is used for reducing circulating lymphocytes in treating relapsing forms of multiple sclerosis in adults. Ponvory uses Ponesimod as an active ingredient. Ponvory was launched by Vanda Pharms Inc in 2021.
Approval Date:
Ponvory was approved by FDA for market use on 18 March, 2021.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Ponvory is 18 March, 2021, its NCE-1 date is estimated to be 18 March, 2025.
Active Ingredient:
Ponvory uses Ponesimod as the active ingredient. Check out other Drugs and Companies using Ponesimod ingredient
Treatment:
Ponvory is used for reducing circulating lymphocytes in treating relapsing forms of multiple sclerosis in adults.
Dosage:
Ponvory is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2MG | TABLET | Prescription | ORAL |
| 4MG | TABLET | Prescription | ORAL |
| 3MG | TABLET | Prescription | ORAL |
| 8MG | TABLET | Prescription | ORAL |
| 5MG | TABLET | Prescription | ORAL |
| 9MG | TABLET | Prescription | ORAL |
| 10MG | TABLET | Prescription | ORAL |
| 6MG | TABLET | Prescription | ORAL |
| 20MG | TABLET | Prescription | ORAL |
| 7MG | TABLET | Prescription | ORAL |